| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MECR |
| Uniprot No | Q9BV79 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 54-373aa |
| 氨基酸序列 | MGSSHHHHHHSSGLVPRGSHMPAKVVELKNLELAAVRGSDVRVKMLAAPI NPSDINMIQGNYGLLPELPAVGGNEGVAQVVAVGSNVTGLKPGDWVIPAN AGLGTWRTEAVFSEEALIQVPSDIPLQSAATLGVNPCTAYRMLMDFEQLQ PGDSVIQNASNSGVGQAVIQIAAALGLRTINVVRDRPDIQKLSDRLKSLG AEHVITEEELRRPEMKNFFKDMPQPRLALNCVGGKSSTELLRQLARGGTM VTYGGMAKQPVVASVSLLIFKDLKLRGFWLSQWKKDHSPDQFKELILTLC DLIRRGQLTAPACSQVPLQDYQSALEASMKPFISSKQILTM |
| 预测分子量 | 37 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于MECR(线粒体烯酰-CoA还原酶)重组蛋白研究的参考文献概述：
1. **"Structural insights into mitochondrial fatty acid synthesis mediated by human MECR"**
- 作者：Smith, J. et al. (2021)
- 摘要：通过X射线晶体学解析人源MECR重组蛋白结构，揭示其催化活性位点及与底物结合机制，阐明其在线粒体脂肪酸延伸中的作用。
2. **"Functional characterization of recombinant MECR in yeast models"**
- 作者：Li, X. & Chen, Z. (2018)
- 摘要：在大肠杆菌中重组表达并纯化MECR蛋白，通过酵母互补实验验证其恢复脂肪酸合成缺陷的功能，证明其保守的烯酰-CoA还原酶活性。
3. **"MECR mutations impair mitochondrial respiration: Recombinant protein studies in Leigh syndrome"**
- 作者：Johnson, A.E. et al. (2020)
- 摘要：构建携带致病突变的MECR重组蛋白，发现突变体酶活显著降低，导致线粒体呼吸链功能障碍，为Leigh综合征的分子机制提供证据。
注：以上文献名为虚拟示例，实际研究中建议通过PubMed/Google Scholar以关键词"MECR recombinant protein"或"mitochondrial enoyl-CoA reductase expression"检索近期论文。
**Background of MECR Recombinant Protein**
MECR (mitochondrial trans-2-enoyl-CoA reductase) is a key enzyme involved in mitochondrial fatty acid synthesis (mtFAS), a conserved pathway critical for cellular energy metabolism and lipid homeostasis. Located in mitochondria, MECR catalyzes the reduction of trans-2-enoyl-CoA intermediates to acyl-CoA derivatives, a crucial step in the elongation cycle of fatty acids. This process is essential for producing lipoic acid, a cofactor required for mitochondrial enzyme complexes, including those in the tricarboxylic acid (TCA) cycle and oxidative phosphorylation. Dysregulation of MECR has been linked to metabolic disorders, neurodegenerative diseases, and mitochondrial dysfunction, highlighting its physiological significance.
Recombinant MECR protein is generated through genetic engineering, typically by cloning the *MECR* gene into expression vectors (e.g., bacterial, yeast, or mammalian systems) to produce purified, functional protein. This approach enables large-scale production for structural and functional studies. Recombinant MECR retains enzymatic activity, allowing researchers to investigate its role in lipid metabolism, substrate specificity, and interactions with mitochondrial proteins.
Applications of MECR recombinant protein span basic research and drug discovery. It aids in elucidating mtFAS mechanisms, modeling metabolic diseases, and screening potential therapeutics targeting mitochondrial disorders. Structural studies using recombinant MECR have provided insights into its catalytic domains and potential mutation-related pathologies, such as autosomal recessive childhood-onset movement disorders linked to *MECR* gene variants. Challenges in production include maintaining proper protein folding and post-translational modifications, often addressed by optimizing expression systems.
Overall, MECR recombinant protein serves as a vital tool for advancing understanding of mitochondrial biology and developing treatments for related diseases.
×
